In this article, we will discuss Olaparib (Drug Interaction-4). So, let’s get started. Avoid concomitant use of strong CYP3A inhibitors such as itraconazole, telithromycin, clarithromycin, ketoconazole, voriconazole, nefazodone, posaconazole, ritonavir, lopinavir/ritonavir, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir or moderate CYPA inhibitors such as amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil. If […]
Category: Olaparib
In this article, we will discuss Olaparib (Drug Interaction-3). So, let’s get started. Drugs That May Increase Olaparib Plasma Concentrations Olaparib is primarily metabolized by CYP3A. In patients (n=57), co-administration of itraconazole, a strong CYP3A inhibitor, increased AUC of olaparib by 170%. A moderate CYP3A inhibitor, fluconazole, is predicted to increase the AUC of olaparib […]
In this article we will discuss Olaparib (Drug Interaction-2)
In this article we will discuss Olaparib (Drug Interaction-1)
In this article, we will discuss Olaparib (Post Marketing Experience). So, let’s get started. Postmarketing Experience The following adverse reactions have been identified during post-approval use of Olaparib capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal […]
In this article, we will discuss Olaparib (Clinical Trials Experience-9). So, let’s get started. The median duration of study treatment was 8.2 months in patients who received Olaparib and 3.4 months in patients who received chemotherapy. Dose interruptions due to an adverse reaction of any grade occurred in 35% of patients receiving Olaparib and 28% […]